Blog

Reposted from Neil Versel, Editor at GenomeWeb CHICAGO – While multiomics seems to be a top biotech buzzword these days, drug discovery and bioinformatics startup Pepper Bio is trying to make a name for itself in the field of transomics. To that end, the Boston-based startup is leveraging support from Merck and other entities as part of an accelerator program to try and hone its strategy for applications such as…

By Jon Hu, CEO and Cofounder of Pepper Bio In the last decade, the tech industry has coined the phrase “software is eating the world.” In this decade, it’s going to be biotech that eats the world. Biotechnology, specifically, bioplatforms, are one of the main innovations changing our generation. Exhibit A: Moderna’s mRNA technology platform, which created the COVID-19 vaccine at an unprecedented rate, has changed how we perceive and interact…

By Jon Hu, CEO and Cofounder of Pepper Bio  In the last century, we’ve seen incredible progress in the treatment and curing of human disease. Yet, scientists and drug developers still lack critical information about the variety of biological components that play a unique role in disease progression. For that reason, 3 out of 5 people worldwide still die of chronic inflammatory diseases, 1 of 6 die from cancer, and…

By Jon Hu and Samantha Dale Strasser, PhD When we met over a decade ago as students at Northwestern University, we were struck by our similar experiences of watching our loved ones suffer from untreatable diseases and fighting our own.  Jon recounts, “when I was diagnosed with severe chronic migraines, doctors were able to find a prophylactic treatment regimen so that I could live a normal life. However, when my…